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A B S T R A C T
Studies on the role of Rho-associated protein kinase (ROCK) in experimental pulmonary artery hypertension
(PAH) relies mainly on the use of pharmacological inhibitors. However, interpreting these data is hampered by
the lack of specificity of commonly utilized inhibitors. To fill this gap, we have selected and characterized a
novel ROCK inhibitor, Compound 3, previously described in a patent. Inhibitory potency of Compound 3 against
enzymatic activity of ROCK-1 and 2 (IC50 = 10 ± 3.1 and 7.8 ± 0.5 nM, respectively) was accompanied by a
strong vasodilating effect in phenylephrine pre-contracted isolated rat pulmonary artery rings (IC50 =
51.7 ± 9.1 nM) as well as in aortic rings (IC50 = 45.5 ± 1.1 nM). Compound 3 showed a remarkable selectivity
towards ROCK 1 and 2 when tested against a large panel (> 400) of human kinases. A partial explanation for its
selectivity is provided from docking simulations within ROCK-1. Pharmacokinetic studies showed that
Compound 3 is suitable for a twice daily administration without significant accumulation upon repeated dosing.
In rats with monocrotaline (MCT)-induced pulmonary hypertension, therapy with Compound 3, (1 and 3mg/kg,
s.c., b.i.d.), started 14 days after induction of the disease, attenuated right ventricle systolic pressure (RVSP)
increase. Morphometric histological analysis showed that Compound 3, at both doses, counteracted MCT-in-
duced medial thickening of lung distal arterioles with an effect comparable to macitentan (10mg/kg, p.o., q.d.).
Compound 3 is a potent and highly selective ROCK inhibitor that ameliorates hemodynamic parameters and
counteracts pulmonary vascular remodeling in experimental PAH.
1. Introduction
Pulmonary arterial hypertension (PAH) is a rare life-threatening
disease characterized by a persistent increase in pulmonary artery
pressure> 25mmHg, which is accompanied by augmented vascular
resistance and remodeling of the vascular walls of both larger- and
smaller-caliber pulmonary artery branches (Schermuly et al., 2011).
PAH treatments relay on the use of prostanoids, endothelin receptor
antagonists (ERAs), phosphodiesterase-5 (PDE5) inhibitors and soluble
guanylate cyclase stimulators (Galiè et al., 2015). Nevertheless, PAH
continues to be a serious clinical problem with high morbidity and
mortality.
Rho-associated coiled-coil forming protein kinases (ROCK), which
are important down-stream effectors of small GTP-binding protein
RhoA, play key roles in pulmonary arterial smooth muscle cells
(PASMC) contraction and proliferation (Riento et al., 2003; Feng et al.,
2016). Two isoforms, ROCK-1 and ROCK-2, have been described and
found expressed in many human and rodent tissues including the heart,
lung and vascular tissue (Oka et al., 2008). ROCK is at the intersection
of signal transduction initiated by several agents regulating vascular
smooth muscle cell contraction and proliferation, including serotonin,
angiotensin II, endothelin I and platelet derived growth factor
(Hartmann et al., 2015; Shi and Wei, 2013). Fasudil, one of the first
discovered ROCK inhibitor, is characterized by a micromolar affinity
for ROCK as well as for other kinases, including PKA, PKG and CaMKII
(LoGrasso and Feng, 2009; Tamura et al., 2005). Fasudil has been ap-
proved for treatment of cerebral vasospasm after subarachnoid he-
morrhage (Satoh et al., 2014) and short-term efficacy of fasudil in the
treatment of PAH has been demonstrated in small clinical trials (Raja,
2012). Y-27632 was originally disclosed as a calcium blocker (Muro
et al., 1990) and reported to be active as relaxant of vascular and
bronchial smooth muscles (Uehata, 1997). Although largely utilized as
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pharmacological tool, Y-27632 shows moderate potency on ROCK and
poor selectivity (Ishizaki et al., 2000) and inhibits voltage-dependent
potassium channels in arterial smooth muscle cells (Li et al., 2016).
Despite their large use, both fasudil and Y-27632 are limited by poor
selectivity and low on-target potency resulting in non-specific phar-
macological and toxic effects (Li et al., 2016; Asano et al., 1998). Few
other ROCK inhibitors have been tested in PAH models. SB-772077-B
decreased pulmonary and systemic arterial pressures in rats with MCT-
induced pulmonary hypertension, but no data were reported on the
effects on vascular remodeling (Dhaliwal et al., 2009). Moreover, re-
latively poor selectivity was reported for SB-772077-B (Doe et al.,
2007). Azaindole-1 (Schirok et al., 2008), an oral ROCK inhibitor,
proved to be effective in PAH induced by MCT or chronic hypoxia
(Dahal et al., 2010). One limitation of this study is that azaindole-1 was
not compared to any of the drugs currently approved for treating PAH
patients.
In a series of ROCK inhibitors previously disclosed in a patent ap-
plication published in 2010, we spotted example 3 (Trans-6-((4-ami-
nocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide), from now re-
ported as Compound 3 (Fig. 1) (Terasawa et al., 2010). Our interest in
Compound 3 was elicited by the pharmacological profile reported and
by its phys-chem properties similarity to fasudil and Y-27632 that could
translate in a similar solubility and bioavailability (Terasawa et al.,
2010).
In this paper we report the extensive pharmacological character-
ization of Compound 3, including potency on target and selectivity,
vasorelaxant potency, pharmacokinetic profile and its hemodynamic
and anti-remodeling effects in a rat model of MCT-induced PAH. The
effect of Compound 3 was compared with macitentan, a dual en-
dothelin-receptor antagonist (ERA) approved for the treatment of PAH
(Galiè et al., 2015).
2. Materials and methods
2.1. Synthesis of Compound 3
Preparation of Compound 3 (Fig. 1) was carried out by adapting the
general synthesis procedure reported previously (Terasawa et al.,
2010).
2.2. Docking simulations
Docking simulations were performed starting from the crystal
structure of human ROCK-1 in complex with hydroxyfasudil (PDB
2ETK) (Jacobs et al., 2006). The preparation of the X-ray structure was
conducted with the Protein Preparation Wizard tool, applying default
parameters. Glide docking grids were centered on the co-crystallized
hydroxyfasudil molecule, setting the enclosing and bounding box sizes
to 40 Å and 15 Å on each side, respectively. Twenty docking solutions
were collected and ranked according to their Emodel score. Only the
best-ranked pose of Compound 3 was retained and analyzed.
2.3. Biochemical enzymatic assays
Glutathione S-transferase (GST)-tagged 1–535 human ROCK1 and
GST-tagged 1–552 human ROCK2 (Fisher Scientific UK Ltd,
Loughborough, Leicestershire, UK) were diluted into assay buffer con-
taining 40mM Tris pH7.5, 20mM MgCl2 0.1mg/ml BSA, 50 μM DTT
and 2.5 μM peptide substrate (myelin basic protein). Test compounds
were dissolved in dimethyl sulphoxide (DMSO) to a final concentration
of 1%. All reactions/incubations were performed at 25 °C. Test com-
pounds and either ROCK1 or 2 were mixed and incubated for 30min.
Reactions were initiated by addition of ATP (10 μM). After a 1 h in-
cubation 10 μl of ADP-Glo Reagent (Promega UK Ltd, Southampton,
UK) was added and after a further 45min incubation 20 μl of Kinase
Detection Buffer added and the mixture incubated for a further 30min.
The luminescent signal was measured on a luminometer. Compounds
were tested in dose-response format. To determine the IC50 data were fit
to a plot of % inhibition vs Log10 compound concentration with a
sigmoidal fit using ActivityBase software (v 8.05, ID Business Solutions
Limited, Guildford, UK).
2.4. Rat isolated pulmonary artery and aorta assays
All the experiments were performed according to Gonzales et al.
(2000), with modifications. Briefly, Wistar rats were anesthetized with
pentobarbital sodium and exsanguinated. Thoracic aortic segments and
pulmonary artery were isolated, cleaned of adventitia and aorta was cut
into 4 rings (2–3mm each). Each preparation was placed in 20-ml
organ bath filled with oxygenated (O2 95% and CO2 5%) normal Krebs-
Henseleit solution and maintained at 37 °C. Aortic preparations were
connected to isometric force transducers under a resting tone of 2 g,
pulmonary artery ring under a resting tone of 1 g. After an equilibration
period of 60min, each preparation was contracted with a maximal
concentration of phenylephrine (PHE) (1 μM). After a thorough
washout, vessels were contracted with PHE (0.1 μM) and, at the steady
tone, a concentration-response curve (CRC) of test substances or vehicle
was constructed. Results were expressed as percent of maximal re-
laxation obtained at the end of CRC by washing the residual PHE-in-
duced contraction.
Some experiments were performed on endothelium-deprived aortic
rings under the same experimental conditions. To verify if the
Fig. 1. Chemical structures of ROCK inhibitors fasudil (1), Y-27632 (2) and Compound 3 (3) as described in the cited patent (WO 2010/032875).
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endothelium was completely removed, carbachol (10 μM) was added to
the PHE (0.1 μM)-contracted aortic rings. The lack of any relaxing effect
proved the absence of endothelium (Lockette et al., 1986). Subse-
quently, the preparations were washed out and re-contracted with PHE
(0.1 μM) and, at the steady-state, CRC of test substances or vehicle were
constructed.
2.5. Animal model of monocrotaline-induced pulmonary hypertension
All the experimental procedures and conditions involving experi-
mental animals were reviewed and approved by the local ethics com-
mittees and authorized by the Italian Ministry of Health (authorization
number 33/2016-PRPAH) and were performed in full compliance with
the international European ethics standards in conformity to directive
2010/63/EU, the Italian legislative decree 116/1992, and the Animals
(Scientific Procedures) Act of 1986. PAH was induced in male Wistar
rats (Charles River) with a single subcutaneous injection of MCT 60mg/
kg. The alkaloid MCT (Sigma) was freshly dissolved in 1 N HCl, and the
pH was adjusted to 7.4 with 1 N NaOH. Control rats received an equal
volume (1ml/kg) of isotonic saline. The animals were weighed three
times weekly and the weight gain was calculated by subtracting the
basal weight to weight at the end of the experiment.
At day 14 post MCT injection rats were randomized into five groups
(n=10) to receive, for two weeks, either saline vehicle (1 ml/kg, b.i.d.,
s.c.), 1 or 3mg/kg of Compound 3 (b.i.d., s.c.), oral vehicle (0.5%
carboxymethyl cellulose in water, 10ml/kg) and macitentan (10mg/
kg, p.o.) once daily.
After 28 days from the MCT induction, rats were subjected to he-
modynamic measurements and, subsequently, killed.
2.6. Measurement of right ventricle pressure and systemic pressure
On day 28, test compounds or vehicle were administrated to ani-
mals two hours before hemodynamic measurements performed by
intra-cardiac catheterization in a blinded manner as described pre-
viously (Budas et al., 2018). Systolic arterial pressure (SAP) recording
was performed under isoflurane/O2 anaesthesia with a saline filled
polyethylene catheter (PE50) inserted into carotid artery which was
connected to a pressure transducer (BLPR, World Precision Instruments,
UK). Thoracotomy was carefully performed to expose the heart and the
right ventricle systolic pressure (RVSP) was recorded with a Millar
catheter. Both Millar catheter and pressure transducer were connected
to an amplifier (TBM4M, World Precision Instruments, UK) and an
acquisition unit (Powerlab 16S, World Precision Instruments). After
stabilization of signal, SAP and RVSP were recorded for at least 15min.
Data were analyzed using a dedicated software, LABCHART (ADIn-
struments, Australia).
After hemodynamic recordings, animals were euthanized with 5%
isoflurane and by exsanguination. Lungs and hearts were collected for
further analyses. The right ventricle free wall (RV) was separated from
the left ventricle and septum (LV+S) to determine the weights and the
RV to LV+S weight ratio (RV/LV+S) (Fulton Index).
2.7. Immunohistochemical and morphometric analysis of pulmonary
arteries
Lung tissues were fixed in 10% formalin and paraffin-embedded.
The paraffin-embedded tissues from the left lungs were sectioned to
yield 3 μm thick sections for immunohistochemical analysis and ex-
amination by light microscopy. The sections were placed on the
Ventana automated stainer BenchMark ULTRA™ ICH system (Ventana
Medical Systems Tucson, AZ). The Ventana staining procedure included
dewax antigen retrieval with cell conditioner 1 and incubation with
primary antibody (actin smooth muscle clone 1A4, Roche Diagnostic)
for 30min at 37 °C. For chromogenic detection, ultraView Universal
RED detection kit (Ventana, Tucson, AZ) was used. Nuclei were
counterstained with Mayer's Hematoxylin. Subsequently, slides were
washed in water with a drop of detergent and mounted.
The circumferential actin smooth muscle antibody positive staining
around vessels reveals the medial area, which represents the area be-
tween the lamina elastica interna and externa. To assess the type of re-
modeling of muscular pulmonary arteries, vessels were analyzed using
a computerized morphometric system (Leica DMD108, Leica
Microsystems, Wetzlar, Germany).
In the first analysis, for each animal at least 40 intra-acinar pul-
monary vessels of 15–60 μm in diameter were selected at a magnifica-
tion of × 100 in randomly selected fields and evaluated for the degree
of muscularization. Each small artery was categorized as: N=Non-
muscularized (no apparent smooth muscle staining); P= Partially
Muscularized (incomplete medial layer of actin smooth muscle
staining) and M=Muscularized (complete medial layer staining), as
previously described (Schermuly et al., 2004). In the second analysis, at
least 40 distal pulmonary arteries of 61–200 μm in external diameter
were divided into two different groups (61–100 μm and 101–200 μm)
and were evaluated for measurement of medial wall thickness at a
magnification of 100× . After external diameter and medial thickness
measurement of each artery, medial thickness was expressed as follows;
percent wall thickness = [(medial thickness ×2)/external diameter]
× 100 (Abe et al., 2004). All analyses were done by two observers,
blinded to the experimental groups.
2.8. Pharmacokinetic measurements and analytical methodology
Lung samples (0.1 g tissue/ml) were homogenised in ammonium
formiate (20mM). 50 μl of tissue homogenate were added to 200 μl of a
cold acetonitrile solution containing the Internal Standard (IS) atenolol
at concentration of 5 μg/ml. After mixing samples were centrifuged for
15min at 13,000× g (5 °C), diluted 1:1 (v/v) with mobile phase A and
injected into LC-MS/MS. Plasma samples were obtained from blood
after centrifugation using tripotassium ethylenediaminetetraacetic acid
as anticoagulant and processed as follow: 50 μl of plasma were added to
200 μl of a cold (4 °C) acetonitrile solution containing the IS at con-
centration of 5 μg/ml. After mixing, samples were centrifuged for
15min at 800× g (5 °C), diluted 1:1 (v/v) with mobile phase A and
injected into LC-MS/MS. Study samples were analyzed using an
ABSciex API 3200 with TurboIonspray interface in positive-ion multiple
reaction-monitoring mode. Each sample was injected sequentially onto
the LCMS/MS system using a Shimadzu prominence UFLC system and
separated using Gemini Nx −5 μ C18 110 A 50×2.00mm as column.
10mM Ammonium Bicarbonate in water, pH8, was used as mobile
phase A and methanol as mobile phase B (flow rate 0.4ml/min). PK
parameters and PK simulations were obtained using Phoenix WinNonlin
(Pharsight Corporation, Sunnyvale, CA) version 6.2.1. Calibration
curves and quality control samples for plasma and lung were prepared
using the same procedure of study samples.
2.9. Statistical analysis
All values are mean± standard error (S.E.M.) of number (n) sub-
jects as indicated in the figures. Statistical analysis was performed using
one- or two-way analysis of variance (ANOVA) followed by Dunnett's or
Bonferroni post-hoc test for multigroup comparisons by using Prism
software (Graph Pad Software, San Diego, CA). P < 0.05 was con-
sidered a level of statistical significance.
3. Results
3.1. Proposed binding mode of Compound 3 within ROCK-1
To investigate the binding mode of Compound 3, docking simula-
tions were conducted using the X-ray structure of human ROCK-1 (PDB
2ETK) (Jacobs et al., 2006). The best-scored pose of Compound 3
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superimposed well with the co-crystallized hydroxyfasudil molecule
(Fig. 2). Compound 3 bound to the hinge region through its carbox-
amide group, forming two hydrogen bond interactions with the back-
bone of Glu154 and Met156 (Fig. 2). Such bidentate interaction was
further strengthened by the presence of an intramolecular hydrogen
bond between the methoxy oxygen and the neighboring amide NH2
(Guo et al., 2016), yielding to the formation of a pseudo bicyclic system
that superimposed well with the isoquinolone ring system of hydro-
xyfasudil. Besides the hinge interactions, Compound 3 formed extensive
hydrophobic contacts with Ile82, Val90, Leu205 and Phe368 through
its pyridine ring (not shown in Fig. 2), while the positively charged 4-
trans-aminocyclohexyl moiety bound to the side chain amide of Asn203
and Asp216.
3.2. Inhibition of ROCK-1 and ROCK-2 enzymatic activity
Enzymatic inhibition potency (IC50) for Compound 3 were de-
termined for both human isoforms of ROCK-1 and ROCK-2 (Table 1).
Compound 3 is a nanomolar inhibitor on both ROCK isoforms, and its
measured IC50 for ROCK-1 (2 nM) is in line with that reported by
Terasawa et al. (2010). ATP competitive behavior of Compound 3 was
inferred by examining its binding mode, which resulted very similar to
other ATP competitive ROCK inhibitors. In conclusion, Compound 3
resulted about ten and sixty times more potent than Y-27632 and fas-
udil, respectively.
3.3. Kinase selectivity
Compound 3 was counter-screened in a competitive assay against a
large panel (> 400) of human kinases, (Kinome Scan®, Discoverx) at
the concentration of 100 nM, about 10× times higher than enzymatic
IC50 on both isoforms. The graphical view of kinome scan is reported in
Fig. 3. Only two hits were detected by setting the threshold for residual
activity below 35%, potentially indicating off-target interactions. The
hit in the CAMK family is the MKNK2 and the hit in the AGC family is
the PRKG2, with 7.8% and 30% of residual activity, respectively. For
both off-target kinases, the percentage of residual activity is higher than
that for ROCK-1 and ROCK-2, 0.05% and 0.25%, respectively.
3.4. Vasorelaxant effects in isolated rat pulmonary artery and aortic rings
The vasorelaxant activity of Compound 3, fasudil and Y-27632 was
assessed on rat pulmonary artery pre-contracted with PHE (1 μM). The
three ROCK inhibitors tested produced relaxation in a concentration-
dependent manner, with Compound 3 showing an IC50 value of
51.7 ± 9 nM, resulting more than 10-fold active respect Y27632 and
fasudil (Fig. 4A). Similarly, in aortic rings pre-contracted with PHE
(1 μM), Compound 3 fully reversed contraction with an IC50 value of
45.5 ± 1.1 nM, showing a> 30-fold higher potency in comparison
with Y27632 and fasudil, respectively (Fig. 4B). When tested in en-
dothelium-deprived aortic rings, Compound 3 showed a potency (IC50
= 50.9 ± 5.2) comparable to that observed when tested in en-
dothelium-intact rings (Fig. 4C).
3.5. Pharmacokinetic
The pharmacokinetic profile of Compound 3 after subcutaneous
administration of a single dose to rat is shown in Fig. 5. Compound 3 is
retained in the lung showing higher concentrations than in plasma
probably due to the high volume of distribution of the compound. A
compartmental PK model was used to simulate lung concentration-time
profile after multiple dose administration using Phoenix WinNonlin
software. All PK parameters were fitted to the observed pharmacoki-
netics on Day 1 and then the lung concentrations were predicted for a
twice daily repeated dose administration over 14 days. The 14-day dose
simulation in the lung confirmed that levels of Compound 3 in the
Fig. 2. Docking of Compound 3 in the x-Ray structure of hydroxyfasudil bound
to human ROCK-1. Compound 3 (yellow) and hydroxyfasudil (green). (For in-
terpretation of the references to color in this figure legend, the reader is referred
to the web version of this article.)
Table 1
Inhibitory potencies (IC50) of Compound 3, fasudil and Y-27632 against enzy-
matic activity of human ROCK isoforms 1 and 2. Where n=4, the values are
means ± standard error of four independent experiments performed in tripli-
cate. Where n= 1, the values are means and confidence intervals of three de-
terminations in a single experiment.
ROCK-1, IC50 (nM) ROCK-2, IC50 (nM)
Compound 3 (n= 4) 10 ± 3.1 7.8 ± 0.5
Y-27632 (n=1) 109 (193-24) 90 (116-62)
fasudil (n= 1) 844 (1174-515) 691 (893-489)
Fig. 3. Dendrogram representation of the human kinome and kinase hits (red
dots) by Compound 3 at 100 nM, demonstrating kinase selectivity through a
KINOMEscan competition binding assay over a large panel (436) of human
kinases. Red dots represent interactions with residual activity below 35%
(>65% inhibition). (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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tissue were constantly at least> 5-fold above the IC50 value
(45.5 ± 1.1 nM) calculated as vasorelaxant effects in isolated rat aortic
rings. Thus, Compound 3 profile proved to be suitable for a twice daily
administration without showing significant accumulation upon re-
peated dosing.
3.6. Effects in the monocrotaline-induced PAH rat model
Male Wistar rats were initially randomized into the six groups
(n=10) and treated with a single injection of MCT (60mg/kg s.c.).
Fourteen days after MCT injection, two-week interventional treatments
with Compound 3 (1 or 3mg/kg, s.c., b.i.d.), macitentan (10mg/kg,
p.o., q.d.) or respective vehicles (subcutaneous saline, b.i.d. and oral
0.5% carboxymethyl cellulose in water, q.d.), were initiated.
Hemodynamic and gravimetric measurements performed four weeks
after MCT induction showed that vehicle-treated rats exhibited severe
elevation of RVSP, and right ventricular hypertrophy compared with
sham control animals (Fig. 6). All rats belonging to the sham group as
well as animals receiving higher dose of Compound 3 (3mg/kg) sur-
vived throughout the twenty-eight days after MCT injection. In con-
trast, in MCT-animals treated with subcutaneous vehicle, lower dose of
Compound 3 (1mg/kg), oral vehicle or macitentan (10mg/kg) the
survival rates were of 70%, 80%, 80% and 90% respectively.
Curative regimens of treatment with Compound 3 or macitentan for
two weeks, significantly reduced RVSP compared to MCT group
(Fig. 6), without affecting heart rate (Table 2). At day 28 MCT-treated
animals showed lower values of SAP compared to healthy animals.
While Compound 3 did not affect this value compared to MCT group,
treatment with macitentan re-established SAP to normal values.
The RV hypertrophy was evident in MCT rats, showing a significant
increased RV/(LV+S) mass ratio (Fulton index) compared with the
healthy rats (0.51 ± 0.03 vs 0.25 ± 0.01; Fig. 6). Treatment with
Compound 3 did not reduce the RV/(LV+S) ratio in comparison with
placebo (0.49 ± 0.03 with 1mg/kg dose, 0.49 ± 0.03 with 3mg/kg
dose). Albeit not significant, macitentan showed a trend of reduction in
RV hypertrophy with a mean mass RV/LV+S ratio of 0.41 ± 0.04.
The exposure to MCT induced a substantial increase in muscular-
ization in intra-acinar pulmonary vessels (15–60 μm in diameter,
Fig. 7). Only 18% of intra-acinar vessels are fully muscularized in
healthy rat lungs and the majority of vessels lacks a muscular layer or
presents just a partial muscularization. Conversely, in MCT treated rats,
muscularized vessels are the majority while less than 5% of vessels lack
a muscular layer. Treatment with Compound 3 and macitentan showed
anti-remodeling effects as evident by the significant reduction in fully
muscularized vessels which is accompanied by the increase in non-
muscularized ones (Fig. 7). Next, we quantified medial wall thickness of
distal pulmonary arteries subdivided in small and medium size ac-
cording to the diameter of the lumen: 61–100 μm and 101–200 μm.
Compared to healthy group, rat exposed to MCT and treated with ve-
hicles showed a significant increase in medial wall thickness of all the
Fig. 4. Concentration-dependent vasorelaxation induced by Compound 3, fasudil and Y-27632 in phenylephrine-pre-contracted rat PA (A), endothelium-intact (B)
and endothelium-deprived (C) rat thoracic aortic rings. The reductions in force caused by the tested compounds are expressed as a percentage of maximal relaxation
measured at the end of CRC by washing the residual PHE-induced contraction. Each data point represents the mean of 7–8 independent experiments± S.E.M.
Fig. 5. Lung (ng/g) and plasma (ng/ml) concentrations of Compound 3 over time after one single subcutaneous administration of 3mg/kg (n= 3) (upper panel).
Prediction of lung concentrations (nM) of Compound 3 upon 14-day repeated subcutaneous administration of 3mg/kg b.i.d. Dotted line represents the IC50 obtained
in the isolated pulmonary rat artery vasorelaxation assay (lower panel).
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three size groups of arteries (Fig. 7). Both Compound 3 and macitentan
significantly reduced the medial thickening of all size groups of arteries,
with Compound 3 showing a dose-dependent reduction.
4. Discussion
The main findings of this study are: 1) Compound 3 is a highly se-
lective ROCK inhibitor and a potent vasorelaxant with an amenable PK
profile for subcutaneous delivery; 2) Compound 3 treatment sig-
nificantly ameliorated hemodynamics and pulmonary vascular re-
modeling in MCT-induced PAH in the rat; 3) the beneficial effects of
Compound 3 are comparable to those obtained, in a head-to-head
comparison, with macitentan and were attained with a interventional
treatment regimen started when the MCT-induced pathology is con-
sidered already progressing.
In the quest for better pharmacological tools for investigating ROCK
pathophysiological functions in PAH, we have focused our attention on
a novel ROCK inhibitor described as Example 3 in an abandoned patent
application (Terasawa et al., 2010) and here indicated as Compound 3.
We further proceeded with a thorough characterization of Compound 3
and found that is a potent inhibitor of both ROCK 1 and 2 at nanomolar
concentrations.
A remarkable selectivity towards ROCK 1 and 2 was found by spot-
testing Compound 3 at 100 nM against a large panel of human kinases.
A partial explanation for its selectivity toward PKA, which is highly
homologue to ROCK, can be provided from docking simulations within
ROCK-1 (Jacobs et al., 2006). Indeed, in the best-scored pose of Com-
pound 3 the methoxy group is buried within a small hydrophobic cleft,
formed by Met153 and Ala215. This latter residue, is substituted with a
threonine in PKA (Thr183). It has already been observed that the in-
creased steric hindrance of this amino acid in PKA compared to ROCK
caused a shift in the orientation of Y-27632 within the ATP-binding site,
providing a structural clue for the slight selectivity exhibited by this
inhibitor towards ROCK-1 (> 30-fold) (Jacobs et al., 2006). Likewise, it
can be hypothesized that the threonine side chain in PKA may hamper a
proper accommodation of the methoxy group of Compound 3, yielding
to a rearrangement of the ligand geometry and the subsequent loss of
the key ligand-protein interactions. That said, it cannot be ruled out
that the remarkable selectivity exhibited by Compound 3 compared to
fasudil and Y-27632 might arise from other complex dynamic me-
chanisms, including induced-fit effects and/or conformational selection
(Agafonov et al., 2014).
By testing Compound 3 in isolated rat pulmonary artery and aortic
rings contracted with PHE, we demonstrated that the inhibitory effects
observed in the enzymatic assays translate into a robust vasorelaxant
activity occurring in the nanomolar range of concentrations. The re-
laxant effect of Compound 3 is markedly superior to vasorelaxation
obtained with fasudil or Y-27632 in head-to head comparisons (> 30-
fold potency difference).
Together, the in vitro data suggest that Compound 3 is not only a
highly selective and potent inhibitor of ROCK but is also a more potent
vasorelaxant agent than fasudil and Y-27632. Therefore, we performed
chronic treatments in experimental PAH induced by MCT in rats to
investigate the therapeutic efficacy of Compound 3. Compound 3 was
tested in a head-to-head comparison with macitentan, an orally active,
potent, dual endothelin (ET) A and B receptor antagonist currently in
use to treat PAH patients. Compared to other endothelin receptor an-
tagonists, macitentan has improved tissue targeting, a longer duration
of action and an improved safety profile (DuBrock and Channick, 2014;
Iglarz et al., 2015). An interventional treatment regimen was adopted
for both macitentan and Compound 3. Treatments started 14 days after
MCT induction when the pathology is considered already initiated and
rapidly progressing (Nogueira-Ferreira et al., 2015). The mechanism by
which MCT treatment leads to PAH is thought to occur initially as an
insult to the pulmonary endothelial cells provoking an inflammatory
response while smooth muscle medial hypertrophy takes place from
about day 14 and increases progressively (Huang et al., 2012; Wilson
et al., 2017). For Compound 3, the posology was established based on
its pharmacokinetic profile and was twice daily treatment by sub-
cutaneous injection. Macitentan posology was chosen based on existing
literature (Iglarz et al., 2008). We found that Compound 3, at both
doses tested (1 and 3mg/kg, b.i.d.), ameliorated PAH induced by MCT
similarly to macitentan. Interestingly, the lowering of blood pressure
was selective for the pulmonary district, as SAP was not significantly
Fig. 6. Effects of 2-week treatment with sub-
cutaneous vehicle (Veh s.c.), Compound 3
(Cpd3, 1 and 3mg/kg, s.c.), oral vehicle (Veh
p.o.) and macitentan (Mac, 10mg/kg, p.o.) on
MCT-induced right ventricle systolic pressure
(RVSP) and right ventricle remodeling. RVSP
was measured invasively by right heart cathe-
terization (left panel). To determine right
ventricular remodeling, the heart was dis-
sected and the ratio of the right ventricle fresh
weight to left ventricle plus septum weight
(RV/LV+S) was calculated (right panel). Each
bar represents the mean± S.E.M (n= 7–10).
*p < 0.01 vs Veh s.c., #p < 0.01 vs Veh p.o.
Table 2
Summary of rat number per group (N) at the beginning and at the end of the treatment, weight gain during the 2-week treatment and end of the procedure systolic
arterial pressure and heart rate measures in the different experimental groups. Values represents the mean± S.E.M.
Sham control MCT +Veh s.c. MCT +Cpd3, 1mg/Kg s.c. MCT +Cpd3, 3 mg/Kg s.c. MCT +Veh p.o. MCT +Mac, 10mg/Kg p.o.
N at start 10 10 10 10 10 10
N at end 10 7 8 10 8 9
Weight Gain, g 133 ± 7a 74 ± 7 83 ± 8 79 ± 9 89 ± 8 80 ± 10
Systolic arterial pressure, mmHg 113 ± 6a 81 ± 6 83 ± 4 76 ± 3 97 ± 5 106 ± 5
Heart Rate, bpm 307 ± 13 293 ± 10 301 ± 13 272 ± 10 283 ± 11 303 ± 8
a significant vs MCT+Veh s.c. One-way ANOVA, Tukey's multiple comparisons test, P < 0.01.
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affected in the treated animals. This may appear in contradiction with
the blood pressure lowering effect of pharmacological ROCK inhibition
reported previously (Kast et al., 2007). However, we must consider that
the acute effect on SAP may gradually disappear upon repeated treat-
ments, because of a tolerance phenomenon already known for this class
of compounds (Kast et al., 2007). Interestingly, no significant effect was
observed on heart rates with any of the treatments adopted, suggesting
that Compound 3 treatment did not result in reflex tachycardia. Our
finding is in line with a previous study reporting the lack of effect on
heart rate of chronic treatment with an oral ROCK inhibitor (azindole-
1) in experimental PAH (Dahal et al., 2010).
The increase in RV heart weight in the vehicle group is consistent
with previous studies in the rat MCT model (Nogueira-Ferreira et al.,
2015). We found no protective effect of Compound 3 on RV hyper-
trophy. In a previous study, fasudil, but not bosentan or sildenafil, was
shown to ameliorate RV hypertrophy in the rat MCT model (Mouchaers
et al., 2010). The different outcome between the two studies could be
explained by the differences in the pathology model. Indeed,
Fig. 7. Effects of chronic treatment with Compound 3 (Cpd3, 1 or 3mg/kg, s.c.) and macitentan (Mac, 10mg/kg, p.o.) on MCT-induced histological changes (A–D).
Representative images of lung specimens (200×) double stained with H&E and alpha-smooth muscle actin (α-SMA) (A). Quantification of the degree of vessel wall
muscularisation in small arterioles (< 60 μm). Arteries that contained> 70% of α-SMA positive-vessel wall area were set as fully muscularized (labelled as M);
arteries with< 4% of α-SMA positive-vessel area were set as non-muscular (labelled as N); 4–70% of α-SMA positive-vessel area were defined as partially mus-
cularized (labelled as P) (B). Quantification of the medial wall thickness in vessels of different sizes: 61–100 μm (C) and 101–200 μm (D). Data presented as
mean± S.E.M. * * P < 0.01 treatment groups vs. respective vehicles (Veh s.c. or p.o.).
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Mouchaers and colleagues induced PAH with 40mg/kg of MCT, a dose
inferior to the 60mg/kg utilized in this study. It should also be con-
sidered that fasudil showed effects unrelated to ROCK inhibition, such
as modulation of autophagy (Iorio et al., 2010), which may have an
impact in the MCT-induced PAH model. Interestingly, we found that
also macitentan did not significantly prevent RV hypertrophy despite a
trend. Although a positive effect of macitentan against MCT-induced RV
hypertrophy was previously reported, it should be noted that the
treatment regimen was preventative as started immediately after MCT
injection and lasted for 4 weeks (Iglarz et al., 2015). Thus, a clear effect
on RV hypertrophy in the MCT rat model may require preventative
treatments or interventional treatments lasting longer than 2 weeks.
However, in the MCT model, the disease progression toward death
might be too short for compensatory mechanisms to develop. As an
alternative, the chronic hypoxia model combined with the VEGFR-2
inhibitor Sugen-5416 (Ciuclan et al., 2011), which is characterized by a
slower disease progression could allow longer treatments, thus per-
mitting to further uncover the potential therapeutic effects of ROCK
inhibitors in PAH, as well as possible differences in comparison with
endothelin antagonists or other established therapies. Although this
study was not designed for determining differences in survival between
groups, it is interesting to notice that higher mortality was observed in
the vehicle-treated group as compared with the group treated with the
high dose of Compound 3. This encouraging pro-survival trend may
reflect a positive effect of Compound 3 in counteracting disease pro-
gression.
Another important finding of this study is that Compound 3 im-
proved also pulmonary vascular remodeling as evident from sig-
nificantly reduced muscularization and medial wall thickness of per-
ipheral pulmonary vessels, an effect comparable to that observed in the
macitentan-treated group. This anti-remodeling effect may be con-
sequent to improved hemodynamics resulting from vasorelaxation as-
sociated with ROCK inhibition. However, induction of apoptosis and
reduction of proliferation of pulmonary artery smooth muscle cells (Liu
et al., 2011) and inflammatory cell migration (Abe at al, 2004) might
also contribute to the attenuation of pulmonary arterial wall re-
modeling upon pharmacological inhibition of ROCK. A limitation of this
study is that important functional cardiac parameters, such as cardiac
output, have not been evaluated and further studies in different ex-
perimental PAH models will be necessary to prove the therapeutic value
of this highly selective ROCK inhibitor. Moreover, we are aware that
research on PAH is characterized by significant discordance between
preclinical findings and clinical results (Bonnet et al., 2017).
By demonstrating that Compound 3 is capable of counteracting
vascular remodeling when treatment is initiated after MCT-induced
pathology is already established and rapidly progressing, we provide
support to the rationale of developing pharmacological agents targeting
ROCK in PAH. Most importantly, we point out to the scientific com-
munity that Compound 3 is a versatile, potent and selective pharma-
cological tool with an amenable pharmacokinetic profile and well tol-
erated upon chronic treatment.
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